1.World Health Organization. Health Aspects of Chemical and Biological Weapons. Geneva: World Health Organization; 1970:98-99.
2.Office of Technology Assessment. US Congress. Proliferation of Weapons of Mass Destruction. Publication OTA-ISC-559. Washington, DC: US Government Printing Office; 1993:53-55.
3.Inglesby, TV, Henderson, DA, Bartlett, JGWorking Group on Civilian Biodefense. Anthrax as a biological weapon: medical and public health management. JAMA. 1999;281 (18):1735–1745.
4.Simon, JD.Biological terrorism. Preparing to meet the threat. JAMA. 1997;278 (5):428–430.
5.Cristy, GA, Chester, CV.Emergency Protection Against Aerosols. Publication ORNL-5519. Oak Ridge, TN: Oak Ridge National Laboratory; 1981.
6.Hatch, TF.Distribution and deposition of inhaled particles in respiratory tract. Bacteriol Rev. 1961;25:237–240.
7.Doolan, DL, Freilich, DA, Brice, GT.The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis. 2007;195 (2):174–184.
8.Webb, GF.A silent bomb: the risk of anthrax as a weapon of mass destruction. Proc Natl Acad Sci U S A. 2003;100 (8):4355–4356.
9.Athamna, A, Athamna, M, Abu-Rashed, N, Medlej, B, Bast, DJ, Rubinstein, E.Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother. 2004;54 (2):424–428.
13.Food and Drug Administration, 2005, Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy Review; Anthrax Vaccine Adsorbed; Final Order. Fed Regist. 2005;70:75180–75198.
14.Grabenstein, JD.Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis. 2008;46 (1):129–136.
15.Sever, JL, Brenner, AI, Gale, AD, Lyle, JM, Moulton, LH, West, DJAnthrax Vaccine Export Committee. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf. 2002;11 (3):189–202.